Filing Flows › Citius Oncology (CTOR) › Q2 FY26 › vs Q1 FY26
Citius Oncology (CTOR) Q2 FY26 vs Q1 FY26 (quarter over quarter)
Citius Oncology's revenue fell $2.3M (-58%) from $3.9M in Q1 FY26 to $1.7M in Q2 FY26.
Citius Oncology, Q2 FY26: revenue $1.7M, net loss $26.6M, operating cash flow −$3.8M. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q2 FY26 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7M | $3.9M | −$2.3M | -58% |
| Other income, net | $1.8M | −$18K | $1.8M | — |
| Income tax benefit | $231K | −$264K | $495K | — |
| Net loss | $26.6M | $5.5M | $21.1M | +381% |
| Costs & expenses | $30.3M | $9.5M | $20.8M | +219% |
| Operating costs | $30.3M | $9.2M | $21.1M | +229% |
| Cost of revenue | $329K | $789K | −$460K | -58% |
| Research & development | $1.1M | $1.0M | $61K | +6% |
| General & admin | $23.6M | $2.9M | $20.8M | +726% |
| Other operating costs | $5.2M | $4.5M | $718K | +16% |
| Operating cash sources | $26.6M | $5.5M | $21.1M | +381% |
| Share-based compensation | $3.5M | $4.0M | −$429K | -11% |
| Working capital & other | $19.3M | −$5.8M | $25.0M | — |
| Cash used in operations | $3.8M | $7.4M | −$3.5M | -48% |
| Net loss absorbed | $26.6M | $5.5M | $21.1M | +381% |
Questions
How much did Citius Oncology's revenue grow quarter over quarter in Q2 FY26?
Citius Oncology's revenue fell $2.3M (-58%) from $3.9M in Q1 FY26 to $1.7M in Q2 FY26.